Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.080
+0.050 (1.65%)
Mar 6, 2026, 4:08 PM HKT

HKG:1349 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
685.8709.4850.731,0311,140
Other Revenue
----0.5
685.8709.4850.731,0311,140
Revenue Growth (YoY)
-3.33%-16.61%-17.50%-9.57%36.76%
Cost of Revenue
-63.4674.0886.2981.02
Gross Profit
685.8645.95776.66944.871,059
Selling, General & Admin
-341.04426.45599.5660.26
Research & Development
-314.16243.76226.85224.39
Other Operating Expenses
841.27.445.396.846.15
Operating Expenses
841.2653.7699.5830.78896.57
Operating Income
-155.4-7.7577.15114.09162.72
Interest Expense
--0.59-3.07-1.54-1.06
Interest & Investment Income
-5.557.9711.2925.89
Currency Exchange Gain (Loss)
-0.15-1.08-0.830.14
Other Non Operating Income (Expenses)
-0.45-0.05-0.42-0.146.21
EBT Excluding Unusual Items
-155.85-2.6980.56122.88193.91
Gain (Loss) on Sale of Investments
--10.41-4.35-1.28-
Gain (Loss) on Sale of Assets
-0.030.31.921.78
Asset Writedown
--3.93-5-1.83-2.15
Other Unusual Items
-22.4626.0210.6122.38
Pretax Income
-155.855.4697.53132.29215.92
Income Tax Expense
1.59-33.98-10.92-4.983.54
Earnings From Continuing Operations
-157.4439.43108.45137.27212.38
Minority Interest in Earnings
-0.30.180.720.92
Net Income
-157.4439.73108.63138213.3
Net Income to Common
-157.4439.73108.63138213.3
Net Income Growth
--63.42%-21.28%-35.30%29.54%
Shares Outstanding (Basic)
1,0371,0371,0341,0301,041
Shares Outstanding (Diluted)
1,0371,0371,0341,0311,045
Shares Change (YoY)
-0.23%0.29%-1.29%5.59%
EPS (Basic)
-0.150.040.110.130.20
EPS (Diluted)
-0.150.040.110.130.20
EPS Growth
--63.51%-19.19%-35.00%20.17%
Free Cash Flow
--59.18-27.9577.96148.78
Free Cash Flow Per Share
--0.06-0.030.080.14
Dividend Per Share
-0.0500.0700.0700.070
Dividend Growth
--28.57%--40.00%
Gross Margin
100.00%91.05%91.29%91.63%92.90%
Operating Margin
-22.66%-1.09%9.07%11.06%14.27%
Profit Margin
-22.96%5.60%12.77%13.38%18.70%
Free Cash Flow Margin
--8.34%-3.29%7.56%13.05%
EBITDA
-101.9145.74129.05186.92216.5
EBITDA Margin
-14.86%6.45%15.17%18.13%18.99%
D&A For EBITDA
53.4953.4951.8972.8353.78
EBIT
-155.4-7.7577.15114.09162.72
EBIT Margin
-22.66%-1.09%9.07%11.06%14.27%
Effective Tax Rate
----1.64%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.